A Phase 1/2, Open Label, Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 03 May 2018
At a glance
- Drugs Dianhydrogalactitol (Primary)
- Indications Adenocarcinoma; Ovarian cancer
- Focus Therapeutic Use
- Acronyms REPROVe
- Sponsors DelMar Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 27 Apr 2018 Planned End Date changed from 1 Dec 2019 to 1 Jun 2020.
- 27 Apr 2018 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2019.